Carl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 4,085 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total value of $191,749.90. Following the completion of the transaction, the insider now owns 255,348 shares in the company, valued at $11,986,035.12. The trade was a 1.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total value of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80.

Apogee Therapeutics Trading Up 1.3 %

Shares of NASDAQ APGE traded up $0.62 during trading hours on Friday, hitting $47.77. 248,646 shares of the company traded hands, compared to its average volume of 266,873. The company's 50 day moving average price is $49.13 and its 200 day moving average price is $48.57. Apogee Therapeutics, Inc. has a 12 month low of $27.05 and a 12 month high of $72.29. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -19.74 and a beta of 2.30.

Institutional Trading of Apogee Therapeutics

Several institutional investors have recently added to or reduced their stakes in APGE. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Apogee Therapeutics during the third quarter valued at $71,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after acquiring an additional 285 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Apogee Therapeutics during the second quarter worth approximately $143,000. Wexford Capital LP bought a new stake in shares of Apogee Therapeutics during the third quarter valued at approximately $230,000. Finally, Intech Investment Management LLC bought a new stake in shares of Apogee Therapeutics during the third quarter valued at approximately $300,000. Institutional investors own 79.04% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on APGE. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a "buy" rating and a $89.00 target price for the company. Canaccord Genuity Group started coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price on the stock. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Thursday, December 12th. Finally, Wedbush upped their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an "outperform" rating in a research note on Monday, December 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.